Market Overview

Transenterix Pops On FDA Clearance For Senhance Indication Expansion

Transenterix Pops On FDA Clearance For Senhance Indication Expansion

Transenterix Inc (NYSE: TRXC) announced Tuesday that its laparoscopic Senhance Surgical System was approved by the FDA for two additional indications. 

What Happened 

The Senhance Surgical System received regulatory clearance for laparoscopic inguinal hernia and laparoscopic cholecystectomy, or gallbladder removal, procedures.

Why It’s Important

With about 760,000 inguinal hernia and 1.2 million laparoscopic cholecystectomy procedures in the U.S. annually, the indication expansion more than doubles the device’s total addressable domestic market beyond 3 million annual operations.

"These expanded procedures are commonly performed at over 95 percent of hospitals in the United States,” President and CEO Todd Pope said in a press release. “We believe this indication expansion will significantly increase the applicability of Senhance to more institutions, particularly those with a busy general surgery practice."

Transenterix’s stock popped 27.2 percent premarket on the news.

What’s Next

Pope alluded in the press release to a regulatory strategy to expand indications beyond laparoscopic colorectal, gynecologic, inguinal hernia and cholecystectomy surgery.

Related Links:

A New Short Report Claims Transenterix's Senhance System Is A 'Commercial Flop'

Transenterix Gains 11% After Sale of Robotic Surgery System

Photo courtesy of Transenterix. 

Posted-In: Senhance Surgical SystemNews Health Care FDA Top Stories General Best of Benzinga


Related Articles (TRXC)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Emerging Market Debt: Reconsidering A Beaten-Up Asset Class

Benzinga's Top Upgrades, Downgrades For May 29, 2018